AUTHOR=Tassiopoulos Apostolos K. , Mofakham Sima , Rubano Jerry A. , Labropoulos Nicos , Bannazadeh Mohsen , Drakos Panagiotis , Volteas Panagiotis , Cleri Nathaniel A. , Alkadaa Leor N. , Asencio Anthony A. , Oganov Anthony , Hou Wei , Rutigliano Daniel N. , Singer Adam J. , Vosswinkel James , Talamini Mark , Mikell Charles B. , Kaushansky Kenneth 

TITLE=D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis

JOURNAL=Frontiers in Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.631335

DOI=10.3389/fmed.2021.631335

ISSN=2296-858X

ABSTRACT=<p><bold>Objective:</bold> Examine the possible beneficial effects of early, D-dimer driven anticoagulation in preventing thrombotic complications and improving the overall outcomes of COVID-19 intubated patients.</p><p><bold>Methods:</bold> To address COVID-19 hypercoagulability, we developed a clinical protocol to escalate anticoagulation based on serum D-dimer levels. We retrospectively reviewed all our first 240 intubated patients with COVID-19. Of the 240, 195 were stratified into patients treated based on this protocol (ON-protocol, <italic>n</italic> = 91) and the control group, patients who received standard thromboprophylaxis (OFF-protocol, <italic>n</italic> = 104). All patients were admitted to the Stony Brook University Hospital intensive care units (ICUs) between February 7th, 2020 and May 17, 2020 and were otherwise treated in the same manner for all aspects of COVID-19 disease.</p><p><bold>Results:</bold> We found that the overall mortality was significantly lower ON-protocol compared to OFF-protocol (27.47 vs. 58.66%, <italic>P</italic> &lt; 0.001). Average maximum D-dimer levels were significantly lower in the ON-protocol group (7,553 vs. 12,343 ng/mL), as was serum creatinine (2.2 vs. 2.8 mg/dL). Patients with poorly controlled D-dimer levels had higher rates of kidney dysfunction and mortality. Transfusion requirements and serious bleeding events were similar between groups. To address any possible between-group differences, we performed a propensity-matched analysis of 124 of the subjects (62 matched pairs, ON-protocol and OFF-protocol), which showed similar findings (31 vs. 57% overall mortality in the ON-protocol and OFF-protocol group, respectively).</p><p><bold>Conclusions:</bold> D-dimer-driven anticoagulation appears to be safe in patients with COVID-19 infection and is associated with improved survival.</p><p><bold>What This Paper Adds:</bold> It has been shown that hypercoagulability in patients with severe COVID-19 infection leads to thromboembolic complications and organ dysfunction. Anticoagulation has been variably administered to these patients, but it is unknown whether routine or escalated thromboprophylaxis provides a survival benefit. Our data shows that escalated D-dimer driven anticoagulation is associated with improved organ function and overall survival in intubated COVID-19 ICU patients at our institution. Importantly, we found that timely escalation of this anticoagulation is critical in preventing organ dysfunction and mortality in patients with severe COVID-19 infection.</p>